Piramal Pharma says US FDA closes inspection at Telangana facility
Sarthak Kumar
Piramal Pharma Limited on Monday informed exchanges that the United States Food and Drug Administration (US FDA) has successfully closed the inspection of its manufacturing facility located at Digwal, Telangana.
In a regulatory filing, the company said the US FDA has issued an Establishment Inspection Report (EIR) for the facility, indicating the successful closure of the inspection process.
The development follows an earlier disclosure made by the company on February 14, 2026 regarding the US FDA inspection at the Telangana-based manufacturing unit.
Piramal Pharma stated that the intimation was submitted on the first working day after receiving the EIR from the US regulator.
An EIR is issued by the US FDA after completion of an inspection and generally indicates that the regulator has classified the inspection as closed.
The Digwal facility forms part of Piramal Pharma’s manufacturing network catering to global pharmaceutical markets. Regulatory clearances and successful inspection closures remain important for Indian pharmaceutical companies with exposure to the US market, as they help maintain supply continuity and support exports.
Piramal Pharma operates across complex hospital generics, contract development and manufacturing (CDMO), and consumer healthcare segments, with manufacturing and distribution operations across multiple geographies.
Disclaimer: This article is for informational purposes only and should not be construed as investment advice.